2022
Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting
Haque LY, Butner JL, Shi JM, Henry S, Deng Y, Ciarleglio MM, Madden LM, Tetrault JM. Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting. Journal Of Addiction Medicine 2022, 16: 333-339. PMID: 34483278, PMCID: PMC9033626, DOI: 10.1097/adm.0000000000000910.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionUrine toxicology resultsDirect acting antiviralsViral load testingSubstance use disordersAddiction treatment programsHCV reinfectionActing antiviralsToxicology resultsUse disordersDirect acting antiviral therapyTreatment programReal-world clinical settingHCV reinfection ratesActing antiviral (DAA) therapyC virus infectionHepatitis C infectionMedical service useCohort of patientsPrimary medical careSubstance use statusAddiction treatment settingsQuality improvement initiativesHCV cureC infection
2017
Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal Of Substance Use And Addiction Treatment 2017, 75: 49-53. PMID: 28237054, DOI: 10.1016/j.jsat.2016.12.014.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOpioid treatment programsPercent of patientsHCV treatmentHCV infectionActing antiviralsTreatment outcomesTreatment programOral HCV treatmentSustained virologic responseHCV treatment outcomesRoutine clinical careOngoing drug useVirologic responseRetrospective studyClinical careGeneral populationPatientsDrug useTreatmentOutcomesAntiviralsInfectionPercentPWID
1999
Tuberculosis chemoprophylaxis using a liquid isoniazid‐methadone admixture for drug users in methadone maintenance
O'Connor PG, Shi JM, Henry S, Durante AJ, Friedman L, Selwyn PA. Tuberculosis chemoprophylaxis using a liquid isoniazid‐methadone admixture for drug users in methadone maintenance. Addiction 1999, 94: 1071-1075. PMID: 10707445, DOI: 10.1046/j.1360-0443.1999.947107112.x.Peer-Reviewed Original ResearchConceptsMethadone maintenanceTuberculosis chemoprophylaxisDrug usersMedian durationDaily doseOpioid-dependent drug usersProspective cohort studyMethadone maintenance programDrug treatment programsCompleting therapyINH chemoprophylaxisINH prophylaxisCohort studyEligible subjectsINH therapyCommon reasonChemoprophylaxisTherapyVitamin B6Treatment programMethadoneIsoniazidSubjectsINHDuration
1998
A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic
O’Connor P, Oliveto A, Shi J, Triffleman E, Carroll K, Kosten T, Rounsaville B, Pakes J, Schottenfeld R. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. The American Journal Of Medicine 1998, 105: 100-105. PMID: 9727815, DOI: 10.1016/s0002-9343(98)00194-6.Peer-Reviewed Original ResearchConceptsPrimary care clinicsPrimary care settingBuprenorphine maintenanceCare clinicsDrug treatment programsHeroin dependenceOpioid useUrine toxicologyCare settingsTreatment programOpioid withdrawal symptomsOpioid-dependent patientsIllicit opioid useThrice weekly basisSecondary outcomesPrimary outcomeMaintenance treatmentWithdrawal symptomsMethadone clinicsPrimary careClinical trialsDrug treatmentEffective treatmentConsecutive weeksCocaine use
1997
Three methods of opioid detoxification in a primary care setting. A randomized trial.
O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals Of Internal Medicine 1997, 127: 526-30. PMID: 9313020, DOI: 10.7326/0003-4819-127-7-199710010-00004.Peer-Reviewed Original ResearchConceptsPrimary care settingOpioid detoxificationCare settingsBuprenorphine groupWithdrawal symptomsDouble-blind clinical trialOpioid-dependent patientsHeroin-dependent patientsPrimary care clinicsWithdrawal symptom scoresSevere withdrawal symptomsDrug treatment programsSubstance abuse treatmentNaltrexone groupCare clinicsSymptom scoresPharmacologic protocolClinical trialsTreatment protocolClonidineTreatment retentionBuprenorphineNaltrexoneTreatment programAbuse treatment